北卡医疗
CN
EN
Home
About Us
Profile
BPI Culture
Milestone
Enterprise structure
Honor
News
Product
Medicine
Pesticide
Quality&EHS
Quality Management
EHS
Manufacturing
R&D
Manufacturing sites
Platform consulting
Review of small molecular targets
Cooperation opportunities
Small molecular targeted products
Contact
Recruitment
Contact
Home
>
Platform consulting>
Small molecular targeted products
Small molecular targeted products
Brand Name
Approval Date
Brand Name
Approval Date
BEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMSBEESCMS
2015
Palbociclib
2015
Lenvatinib Mesylate
2014
Ceritinib
2014
Apatinib Mesylate
2014
Idelalisib
2013
Dabrafenib Mesylate
2013
Ibrutinib
2013
Trametinib Dimethyl Sulfoxide
2012
Ponatinib Hydrochloride
2012
Axitinib
2012
Bosutinib Monohydrate
2012
Cabozantinib S-malate
2012
Regorafenib Monohydrate
2011
Vemurafenib
2011
Vandetanib
2011
Icotinib Hydrochloride
2011
Ruxolitinib Phosphate
2011
Crizotinib
2009
Pazopanib Hydrochloride
2007
Nilotinib Hydrochloride Hydrate
2007
Lapatinib Ditosylate Monohydrate
2006
Dasatinib Monoydrate
2006
Sunitinib Malate
2005
Sorafenib Tosylate
2013
Afatinib Dimaleate
2004
Erlotinib Hydrochloride
2002
Gefitinib
2001
Imatinib Mesylate
ob欧宝体育_OB欧宝体育_ob欧宝体育app-欢迎你